He/him

Dr. John Bell is a world-renowned thought leader in oncolytic virus research and development. In addition to his many academic contributions to the field, Dr. Bell established a GMP manufacturing program that has produced clinical grade oncolytic viruses for worldwide use in phase I and II clinical trials. Dr. Bell co-founded and was the Chief Scientific Officer of Jennerex Biotherapeutics (acquired by SillaJen). Dr. Bell also co-founded Turnstone LP, an enterprise linking four Canadian research institutes to drive the clinical and commercial development of a proprietary next-generation oncolytic vaccine platform. He is a Senior Scientist with The Ottawa Hospital and Professor of Medicine and Biochemistry, Microbiology and Immunology at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium and is the Director of the Biotherapeutics Program for OICR. He’s the Scientific Director of BioCanRx, and a fellow of the Royal Society of Canada.